Kisspeptin-10: Published Research

Introduction

Kisspeptin-10 (KP-10) has been the subject of published research spanning in vitro pharmacology, rodent and non-human primate preclinical models, and controlled human neuroendocrine studies. The body of literature focuses primarily on KP-10's activity at KISS1R in the context of the hypothalamic–pituitary–gonadal (HPG) axis, receptor pharmacology, structure-activity relationships, and comparative isoform biology. This article summarizes the published research record, organized by methodology type, with attribution to primary sources.

Methodology Types in the Published Literature

Research on KP-10 has employed several experimental approaches. In vitro pharmacology studies have used cells heterologously expressing KISS1R to characterize receptor binding, signal transduction, and structure-activity relationships. Ex vivo preparations have been used to assess direct effects on GnRH neuron firing and secretion in hypothalamic slice or nerve terminal preparations. Rodent in vivo studies have measured LH and FSH responses following central (intracerebroventricular) and peripheral administration of KP-10 under acute and sustained conditions. Ovine and non-human primate models have extended findings across species with closer reproductive neuroendocrine architecture to humans. Clinical studies — primarily conducted at Imperial College London under the supervision of Waljit Dhillo and colleagues — have administered KP-10 to healthy volunteers and individuals with specific reproductive endocrine phenotypes in controlled trial settings.

Summary of Published Studies

Receptor Binding and In Vitro Pharmacology

Kotani and colleagues (2001), in the paper identifying kisspeptins as GPR54 ligands, reported that KP-10, KP-13, KP-14, and KP-54 all bound GPR54 and stimulated inositol phosphate release with similar potency in Chinese hamster ovary (CHO) cells stably expressing the receptor [1]. The intracellular signaling cascade that follows KISS1R activation is described in the companion mechanism of action article. The authors concluded that receptor activation efficacy was retained in the minimal C-terminal decapeptide fragment — a finding that positioned KP-10 as a tractable research tool with equivalent intrinsic pharmacodynamics to its longer isoforms.

Structure-activity relationship (SAR) studies characterized the binding pharmacophore of KP-10. Niida and colleagues (2006) reported systematic N-terminal truncation and alanine-substitution experiments on KP-10-related peptides, identifying Phe-6, Arg-9, and the C-terminal Phe-10-NH₂ as residues critical for KISS1R agonist activity [2]. The C-terminal amide was identified as essential — its removal resulted in marked loss of receptor activation. NMR and molecular modeling analyses indicated that KP-10 adopts a helicoidal conformation between Asn-4 and Tyr-10 in solution [2].

Roseweir and colleagues (2009) reported the development of the first potent KISS1R peptide antagonists — including peptide 234 — derived from KP-10 by amino acid substitution [3]. These pharmacological tools enabled subsequent research to dissect the physiological role of endogenous kisspeptin signaling in GnRH pulse generation through blockade rather than solely genetic approaches, opening a new branch of KISS1R mechanistic investigation.

Preclinical In Vivo Studies

Dhillo and colleagues (2005) reported the first characterization of kisspeptin's effects in male rats, demonstrating that subcutaneous administration of kisspeptin-54 was associated with measurable plasma LH and testosterone in intact male rats [4]. The same publication documented that central kisspeptin administration produced GnRH release into cerebrospinal fluid — establishing the in vivo functional framework subsequently applied to KP-10 research.

In rodent studies comparing isoforms, pharmacokinetic modeling by Patel and colleagues (2017) reported that the differential in vivo potency between KP-54 and KP-10 was explained primarily by pharmacokinetic differences — particularly the considerably longer plasma half-life of KP-54 (approximately 32 minutes) versus KP-10 (approximately four minutes) — rather than intrinsic pharmacodynamic differences at KISS1R [5]. This finding informed design of extended-half-life KP-10 analogs.

The KNDy neuron hypothesis — proposing that arcuate nucleus neurons co-expressing kisspeptin, neurokinin B, and dynorphin A constitute the GnRH pulse generator — has been examined using KP-10 as a research tool. Lehman and colleagues (2010) reviewed the evidence from genetic, immunohistochemical, and pharmacological experiments in rodents and sheep supporting this model, with kisspeptin as the output signal from KNDy neurons to GnRH neurons [6]. KP-10's short half-life and selectivity make it useful for acute-activation experiments within this circuit.

Human Neuroendocrine Studies

A productive series of controlled human studies has characterized KP-10's neuroendocrine activity in healthy volunteers. Chan and colleagues (2011) published the first systematic characterization of KP-10's effects in healthy men in the Journal of Clinical Endocrinology and Metabolism [7]. The investigators administered intravenous bolus doses of KP-10 across a range and observed a rapid, dose-dependent rise in serum LH. Continuous KP-10 infusion was reported to be associated with elevated mean LH, increased LH pulse frequency, and elevated serum testosterone. Deconvolution analysis of the LH secretory profile led the authors to conclude that KP-10 appeared to act on GnRH pulse frequency as well as amplitude.

Jayasena and colleagues (2015), also at Imperial College London, published a direct comparison of intravenous KP-10, KP-54, and GnRH in healthy men [8]. Both kisspeptin isoforms produced comparable LH responses in humans — in contrast to rodent data that suggested KP-54 superiority — supporting the Patel et al. pharmacokinetic interpretation. The study reported no serious adverse events and no significant effects on blood pressure or heart rate at the kisspeptin doses employed, noting a favorable tolerability profile across the participants studied.

A study by Jayasena and colleagues (2011) examined the sexual dimorphism of KP-10 responses, reporting that women showed greater LH responses to KP-10 than men at equivalent doses, and that the LH response varied across the menstrual cycle [9]. Related sexually dimorphic neuroendocrine responses have also been characterized for oxytocin acetate, another hypothalamic GPCR-targeted peptide studied in controlled human trials. The authors attributed this variation to differences in endogenous estradiol levels, which modulate kisspeptin neuron activity through estrogen receptor alpha — a finding that has informed the design of subsequent sex-stratified research into KISS1R pharmacology.

Structure-Activity and Analog Research

Following characterization of the KP-10 pharmacophore, several research groups developed modified KP-10 analogs with extended plasma half-lives. Tomita and colleagues (2009) reported a KP-10 analog incorporating D-amino acid substitutions that exhibited greater in vivo bioactivity and a prolonged LH response compared to unmodified KP-10 in rodent models, without loss of KISS1R selectivity [10]. These analog studies advance understanding of structure-activity relationships and the properties that govern KISS1R agonism in in vivo contexts.

Active Research Frontiers

The published KP-10 literature identifies several productive areas for continued investigation. The relative contributions of direct GnRH neuron stimulation (via hypothalamic KISS1R) versus indirect routes — including KISS1R on hypothalamic interneurons and peripheral kisspeptin-responsive tissues — to the in vivo LH response following systemic administration continue to be refined. Evidence from species comparison and route-of-administration studies is consistent with central access playing a role in GnRH neuron body activation, while effects at median eminence axon terminals may be accessible by peripheral peptide [3] — a distinction with implications for analog targeting strategies.

Research-grade kisspeptin-10 verified by third-party analytical testing is available for laboratory use. The published clinical research base, while internally consistent, has been conducted predominantly in healthy volunteers. Extending the characterization of KP-10's reported neuroendocrine effects to additional research populations, and across independent research centers, represents an active direction for the field.

Tachyphylaxis — attenuation of LH response observed during some continuous infusion paradigms with kisspeptin isoforms — has been documented in published reports [8]. The molecular mechanisms underlying this phenomenon and its reversibility have been characterized in rodent data and are under active investigation in human studies. Understanding these dynamics is relevant to the design of sustained-activation research paradigms.

The pharmacological significance of peripheral KISS1R populations — including expression in placenta, ovary, testis, and cardiovascular tissue reported in published distribution studies [7, 8] — and the physiological role of circulating kisspeptin on these tissues represent a growing research frontier beyond the core HPG axis signaling literature.

References

1. Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. PMID: 11457843. DOI: 10.1074/jbc.M104847200

2. Niida A, Wang Z, Tomita K, Oishi S, Tamamura H, Otaka A, et al. Design and synthesis of downsized metastin (45–54) analogs with maintenance of high GPR54 agonistic activity. Bioorg Med Chem Lett. 2006;16(1):134-137. PMID: 16214345. DOI: 10.1016/j.bmcl.2005.09.054

3. Roseweir AK, Kauffman AS, Smith JT, Guerriero KA, Morgan K, Pielecka-Fortuna J, et al. Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation. J Neurosci. 2009;29(12):3920-3929. PMID: 19321789. DOI: 10.1523/JNEUROSCI.5740-08.2009

4. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in male rats. J Clin Endocrinol Metab. 2005;90(12):6609-6615. PMID: 16174713. DOI: 10.1210/jc.2005-1468

5. d'Anglemont de Tassigny X, Jayasena CN, Murphy KG, Dhillo WS, Colledge WH. Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. Am J Physiol Endocrinol Metab. 2017;313(2):E149-E154. PMID: 28464043. DOI: 10.1152/ajpendo.00056.2017

6. Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010;151(8):3479-3489. PMID: 20501670. DOI: 10.1210/en.2010-0022

7. Chan YM, Butler JP, Pinnell NE, Pralong FP, Crowley WF Jr, Ren C, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1315-E1319. PMID: 21632807. DOI: 10.1210/jc.2011-0265

8. Jayasena CN, Comninos AN, Nijher GM, Abbara A, De Silva A, Veldhuis JD, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod. 2015;30(8):1934-1942. PMID: 26089302. DOI: 10.1093/humrep/dev135

9. Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. PMID: 19820026. DOI: 10.1210/jc.2009-0406

10. Tomita K, Narumi T, Niida A, Oishi S, Ohno H, Fujii N. A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10. Peptides. 2009;30(7):1323-1327. PMID: 19250962. DOI: 10.1016/j.peptides.2009.03.006